[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-with-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-with-diabetes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100614846","phase-3-efficacy-and-safety-of-ribupatide-administered-once-weekly-in-participants-living-with-obesity-or-overweight-and-diabetes-100614846",false,"NCT07284901","Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","KaiNETIC-2","Key Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus (T2DM).\n* Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and\u002For exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatment naïve if they have an HbA1c of 6.5% to 7.5%, inclusive.\n* BMI ≥27 kg\u002Fm\\^2.\n* History of being unresponsive to at least 1 self-reported effort to lose weight with diet and\u002For exercise in the last 6 months.\n\nKey Exclusion Criteria:\n\n* Current diagnosis or history of type 1 diabetes mellitus (T1DM) or any other type of diabetes except T2DM.\n* History of diabetic ketoacidosis or hyperosmolar state\u002Fcoma within 1 year prior to Screening.\n* History of severe hypoglycemia or hypoglycemia unawareness within 1 year prior to Screening.\n* Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.\n* Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.\n* Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.\n* Uncontrolled hypertension or unstable cardiovascular disease.\n* History of chronic or acute pancreatitis.\n* Known clinically significant gastric emptying abnormality or chronic treatment with medications that directly affect gastrointestinal (GI) motility if taken for \\>30 days continually within 3 months prior to Screening.\n* History of suicide attempt.\n* History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within 2 years prior to Screening.\n* Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonists, GLP-1\u002Fglucose-dependent insulinotropic polypeptide (GIP) agonists, glucagon receptor agonists, or other weight loss medications or treatments aside from diet and exercise within 3 months prior to Screening.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.","ALL","18 Years",{"count":20,"type":21},1156,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on:\n\n* Percent change in body weight\n* Change in hemoglobin A1c (HbA1c)",[27,28],"Obesity With Diabetes","Overweight With Diabetes",[30,31,32,33,34,35,36,37,38],"Obesity","Overweight","Ribupatide","KAI-9531","Glucagon-like peptide-1","GLP-1","Diabetes","Glucose-dependent Insulinotropic Peptide","GIP","RECRUITING","2026-09-02",{"date":42,"type":43},"2026-09-03","ACTUAL",{"date":45,"type":43},"2026-01-12",{"date":47,"type":21},"2028-04-24",{"name":49,"class":50},"Kailera","INDUSTRY",167]